Immediate Impact

23 standout
Sub-graph 1 of 11

Citing Papers

Management of chronic myeloid leukemia in 2023 – common ground and common sense
2023 Standout
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
2023 Standout
2 intermediate papers

Works of Giuseppina Loglisci being referenced

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
2011
“Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia
2010

Author Peers

Author Last Decade Papers Cites
Giuseppina Loglisci 188 129 50 57 22 273
Elisa Cerqui 197 80 90 58 18 278
R. de Paz 132 45 39 56 21 274
H. Deicher 86 56 38 53 26 327
Douglas Tremblay 187 173 86 41 20 319
Ambra Di Veroli 219 114 86 37 30 321
J.G. Fuzibet 149 60 80 62 36 328
Vincenzo Federico 147 80 40 67 26 238
Durjoy K. Shome 141 80 31 19 31 225
Chiara Frairia 141 86 84 95 24 284
Said Mohamed 120 58 43 57 27 248

All Works

Loading papers...

Rankless by CCL
2026